Join
Live feed
·
PRReleasevia Quantisnow
Biogen Inc. logo
Stoke Therapeutics Inc. logo

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
BIIB· Biogen Inc.STOK· Stoke Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BIIB (Biogen Inc.), STOK (Stoke Therapeutics Inc.) and more on Quantisnow.